End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
118.9 BDT | +0.68% | -2.46% | -18.67% |
Strengths
- Its low valuation, with P/E ratio at 9.67 and 7.88 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.67% | 452M | - | ||
+32.09% | 693B | C+ | ||
+29.39% | 584B | B | ||
-1.34% | 372B | C+ | ||
+20.34% | 332B | B- | ||
+7.39% | 294B | C+ | ||
+14.25% | 239B | B+ | ||
-3.03% | 211B | A+ | ||
+10.02% | 210B | B- | ||
+8.49% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- BXPHARMA Stock
- Ratings Beximco Pharmaceuticals Limited